Quick answers
- What is Luspatercept used for?
- The FDA-approved label (Reblozyl, Celgene Corporation, February 27, 2026) says: “REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Luspatercept have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Luspatercept?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Luspatercept been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Luspatercept?
- 1 company lists prescription products of Luspatercept in the FDA NDC Directory, including Celgene Corporation.
What Luspatercept is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. …
— FDA label: Reblozyl, Celgene Corporation, effective February 27, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Injection, powder, lyophilized, for solution |
|---|---|
| Route | Subcutaneous |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Reblozyl |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Celgene Corporation2 products
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA761136 REBLOZYL | Celgene Corp | November 8, 2019 | 5, latest October 20, 2026 2026: Labeling · 2026: Labeling · 2024: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2262906, 2262911, 2262913, 2262915 |
|---|---|
| SPL set ID of the quoted label | 82f4d266-3f52-41eb-86ba-0abf3cf468e8 |
| FDA labels (SPL) | 1 |
| FDA applications | BLA761136 |
| Active ingredients (FDA) | LUSPATERCEPT |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Reblozyl, Celgene Corporation, effective February 27, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →